Roger Inhorn, MD
Medical Oncology · Rockport, MENPI 1831137405
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $204 of the $265 with a category attached, or 77.0%. 6 manufacturers reported payments, led by Gilead at 46.4% of the total. 2025 is the largest year on record at $111, 4.0 times the $28 reported in 2019.
Across 7 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$123
- Tempus AI, Inc$69
- Novartis$24
- Daiichi Sankyo Inc.$21
- Pfizer$15
- Eisai Inc.$13
Across 6 payments — averaging $118,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$695K
- AstraZeneca$12K
- Incyte Corporation$4K
- Bayer$3K
What the payments were for
- Food & beverage$20477%
- Education$6123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $123 |
| Tempus AI, Inc | 1 | $69 |
| Novartis | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Pfizer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$111
How this compares
Too few medical oncology providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 19 | $328,589 |
| Lenalidomide | 24 | $313,580 |
| RevlimidLenalidomide | 15 | $282,519 |
| IbrancePalbociclib | 16 | $271,221 |
| ImbruvicaIbrutinib | 15 | $221,067 |
| PomalystPomalidomide | 13 | $211,948 |
| VenclextaVenetoclax | 14 | $177,140 |
| EliquisApixaban | 62 | $54,078 |
| Abiraterone Acetate | 29 | $39,742 |
| XareltoRivaroxaban | 15 | $10,190 |
| Exemestane | 12 | $4,386 |
| Letrozole | 91 | $3,112 |
| Fentanyl | 12 | $1,593 |
| Anastrozole | 66 | $1,381 |
| Tamoxifen Citrate | 42 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $15 | $325,29978 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Maineon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Rockport
- Marilyn McLaughlinYork$9K
- Peter RubinBiddeford$8K
- Scot RemickScarborough$5K
- Peter WesterveltBrunswick$5K
- Andrew HertlerAugusta$5K
- Matthew KulkeSouth Portland$1K
- George PolkinghornBrunswick$808
- Sneha PurveyAugusta$726
- Colleen YavarowYork$578
- John GulloBrunswick$567
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.